inclusion criteria: - confirmed or highly suspected early stage severe acute respiratory syndrome coronavirus 2 (sars-cov-2), disease with clinical suspicion score >6/20, not requiring hospitalization - age ≥18 years - willing to sign the informed consent form - willing to take study drug or placebo as directed for 21 days

inclusion criteria: - confirmed or highly suspected early stage severe acute respiratory syndrome coronavirus 2 (sars-cov-2), disease with clinical suspicion score >6/20, not requiring hospitalization - age ≥18 years - willing to sign the informed consent form - willing to take study drug or placebo as directed for 21 days